Download PDF
Semin Thromb Hemost 2007; 33(4): 303-312
DOI: 10.1055/s-2007-976164
Copyright © 2007 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Incidence and Pathogenesis of Thrombosis in Hematologic Malignancies

Hau C. Kwaan1 , Brian Vicuna1
  • 1Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
Further Information

Publication History

Publication Date:
24 May 2007 (online)

    Permissions and Reprints

ABSTRACT

Recent surveys have indicated that thromboembolic complications are at least as common in hematologic malignancies, if not more frequent, than in solid tumors. The pathogenesis of thrombosis is similar to that in solid tumors, but with additional factors unique in several forms of hematologic malignancies, as seen in acute promyelocytic leukemia, myeloma, and myeloproliferative disorders. Likewise, the factors contributing to bleeding are similar to those seen in solid tumors, with the exception of a higher frequency of thrombocytopenia.

KEYWORDS

Leukemia - lymphoma - procoagulants - thrombosis - bleeding

REFERENCES

  • 1 Trousseau A. Phlegmasia alba dolens. In: Clinique Medicale de l'Hotel-Dieu de Paris. Paris; Balliere 1865: 654-712
    Google Scholar
  • 2 Bariety M. Tribute to Armand Trousseau (14 October 1801-23 June 1867).  Bull Acad Natl Med. 1967;  151(31) 627-635
    PubMedGoogle Scholar
  • 3 Billroth T. Lectures on surgical pathology and therapeutics. In: A Handbook for Students and Practitioners. London; The New Sydenham Society 1878
    Google Scholar
  • 4 Rickles F R, Levine M N. Epidemiology of thrombosis in cancer.  Acta Haematol. 2001;  106(1-2) 6-12
    Google Scholar
  • 5 Tefferi A, Elliot M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F.  Semin Thromb Hemost. 2007;  33 313-320
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Zangari M, Elice F, Fink L, Tricot G. Hemostatic dysfunction in paraproteinemias and in amyloidosis.  Semin Thromb Hemost. 2007;  33 339-349
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 White R H, Chew H K, Zhou H et al.. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults.  Arch Intern Med. 2005;  165(15) 1782-1787
    CrossrefPubMedGoogle Scholar
  • 8 De Stefano V, Sora F, Rossi E et al.. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment.  J Thromb Haemost. 2005;  3(9) 1985-1992
    CrossrefPubMedGoogle Scholar
  • 9 Khorana A A, Francis C W, Culakova E, Fisher R I, Kuderer N M, Lyman G H. Thromboembolism in hospitalized neutropenic cancer patients.  J Clin Oncol. 2006;  24(3) 484-490
    CrossrefPubMedGoogle Scholar
  • 10 Blom J W, Doggen C J, Osanto S, Rosendaal F R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis.  JAMA. 2005;  293(6) 715-722
    CrossrefPubMedGoogle Scholar
  • 11 Sakuma M, Fukui S, Nakamura M et al.. Cancer and pulmonary embolism: thrombotic embolism, tumor embolism, and tumor invasion into a large vein.  Circ J. 2006;  70(6) 744-749
    CrossrefPubMedGoogle Scholar
  • 12 Mohren M, Markmann I, Jentsch-Ullrich K, Koenigsmann M, Lutze G, Franke A. Increased risk of thromboembolism in patients with malignant lymphoma: a single-centre analysis.  Br J Cancer. 2005;  92(8) 1349-1351
    CrossrefPubMedGoogle Scholar
  • 13 Goldschmidt N, Linetsky E, Shalom E, Varon D, Siegal T. High incidence of thromboembolism in patients with central nervous system lymphoma.  Cancer. 2003;  98(6) 1239-1242
    CrossrefPubMedGoogle Scholar
  • 14 Komrokji R S, Uppal N P, Khorana A A et al.. Venous thromboembolism in patients with diffuse large B-cell lymphoma.  Leuk Lymphoma. 2006;  47(6) 1029-1033
    CrossrefPubMedGoogle Scholar
  • 15 Mohren M, Markmann I, Jentsch-Ullrich K, Koenigsmann M, Lutze G, Franke A. Increased risk of venous thromboembolism in patients with acute leukaemia.  Br J Cancer. 2006;  94(2) 200-202
    CrossrefPubMedGoogle Scholar
  • 16 Ziegler S, Sperr W R, Knobl P et al.. Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis.  Thromb Res. 2005;  115(1-2) 59-64
    CrossrefPubMedGoogle Scholar
  • 17 Virchow R. Phlogose und Thrombose in Gefabsystem. In: Gesammelte Abhandlungen zur Wissenschaftlichen medizin. Frankfurt, Germany; Von Meidinger Sohn 1856: 458
    Google Scholar
  • 18 Gale A J, Gordon S G. Update on tumor cell procoagulant factors.  Acta Haematol. 2001;  106(1-2) 25-32
    CrossrefPubMedGoogle Scholar
  • 19 Falanga A. Thrombophilia in cancer.  Semin Thromb Hemost. 2005;  31(1) 104-110
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Kwaan H C, Parmar S, Wang J. Pathogenesis of increased risk of thrombosis in cancer.  Semin Thromb Hemost. 2003;  29(3) 283-290
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Negaard H, Dahm A, Sandset P M, Iversen P O, Ostenstad B. Angiogenesis and hemostasis in hematological neoplasias.  Curr Drug Targets. 2005;  6(6) 683-699
    CrossrefPubMedGoogle Scholar
  • 22 Rickles F R, Shoji M, Abe K. The role of the hemostatic system in tumor growth, metastasis, and angiogenesis: tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer.  Int J Hematol. 2001;  73(2) 145-150
    CrossrefPubMedGoogle Scholar
  • 23 Bach R R. Tissue factor encryption.  Arterioscler Thromb Vasc Biol. 2006;  26(3) 456-461
    CrossrefPubMedGoogle Scholar
  • 24 Bach R, Gentry R, Nemerson Y. Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine.  Biochemistry. 1986;  25(14) 4007-4020
    CrossrefPubMedGoogle Scholar
  • 25 Kamikura Y, Wada H, Nobori T et al.. Elevated levels of leukocyte tissue factor mRNA in patients with venous thromboembolism.  Thromb Res. 2005;  116(4) 307-312
    CrossrefPubMedGoogle Scholar
  • 26 Sase T, Wada H, Yamaguchi M et al.. Haemostatic abnormalities and thrombotic disorders in malignant lymphoma.  Thromb Haemost. 2005;  93(1) 153-159
    PubMedGoogle Scholar
  • 27 Kamikura Y, Wada H, Sase T et al.. Hemostatic abnormalities and leukocyte activation caused by infection in patients with malignant lymphoma during chemotherapy.  Thromb Res. 2006;  117(6) 671-679
    CrossrefPubMedGoogle Scholar
  • 28 Korte W. Changes of the coagulation and fibrinolysis system in malignancy: their possible impact on future diagnostic and therapeutic procedures.  Clin Chem Lab Med. 2000;  38(8) 679-692
    CrossrefPubMedGoogle Scholar
  • 29 Nadir Y, Katz T, Sarig G et al.. Hemostatic balance on the surface of leukemic cells: the role of tissue factor and urokinase plasminogen activator receptor.  Haematologica. 2005;  90(11) 1549-1556
    PubMedGoogle Scholar
  • 30 Falanga A, Gordon S G. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue.  Biochemistry. 1985;  24(20) 5558-5567
    CrossrefPubMedGoogle Scholar
  • 31 Falanga A, Consonni R, Marchetti M et al.. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells.  Blood. 1998;  92(1) 143-151
    PubMedGoogle Scholar
  • 32 Olas B, Mielicki W P, Wachowicz B, Krajewski T. Cancer procoagulant stimulates platelet adhesion.  Thromb Res. 1999;  94(3) 199-203
    CrossrefPubMedGoogle Scholar
  • 33 Lisman T, de Groot P G, Meijers J C, Rosendaal F R. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis.  Blood. 2005;  105(3) 1102-1105
    CrossrefPubMedGoogle Scholar
  • 34 Lyons R M, Keski-Oja J, Moses H L. Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium.  J Cell Biol. 1988;  106(5) 1659-1665
    CrossrefPubMedGoogle Scholar
  • 35 Wilson E L, Jacobs P, Dowdle E B. The secretion of plasminogen activators by human myeloid leukemic cells in vitro.  Blood. 1983;  61(3) 568-574
    PubMedGoogle Scholar
  • 36 Wilson E L, Jacobs P, Dowdle E B. The effects of dexamethasone and tetradecanoyl phorbol acetate on plasminogen activator release by human acute myeloid leukemia cells.  Blood. 1983;  61(3) 561-567
    PubMedGoogle Scholar
  • 37 Cancelas J A, Garcia-Avello A, Garcia-Frade L J. High plasma levels of plasminogen activator inhibitor 1 (PAI-1) in polycythemia vera and essential thrombocythemia are associated with thrombosis.  Thromb Res. 1994;  75(5) 513-520
    CrossrefPubMedGoogle Scholar
  • 38 Folsom A R, Cushman M, Heckbert S R, Rosamond W D, Aleksic N. Prospective study of fibrinolytic markers and venous thromboembolism.  J Clin Epidemiol. 2003;  56(6) 598-603
    CrossrefPubMedGoogle Scholar
  • 39 Martin S J, Reutelingsperger C P, McGahon A J et al.. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl.  J Exp Med. 1995;  182(5) 1545-1556
    CrossrefPubMedGoogle Scholar
  • 40 Fadok V A, Voelker D R, Campbell P A, Cohen J J, Bratton D L, Henson P M. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages.  J Immunol. 1992;  148(7) 2207-2216
    PubMedGoogle Scholar
  • 41 Flynn P D, Byrne C D, Baglin T P, Weissberg P L, Bennett M R. Thrombin generation by apoptotic vascular smooth muscle cells.  Blood. 1997;  89(12) 4378-4384
    PubMedGoogle Scholar
  • 42 Casciola-Rosen L, Rosen A, Petri M, Schlissel M. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus.  Proc Natl Acad Sci USA. 1996;  93(4) 1624-1629
    CrossrefPubMedGoogle Scholar
  • 43 Fibach E, Treves A, Korenberg A, Rachmilewitz E A. In vitro generation of procoagulant activity by leukemic promyelocytes in response to cytotoxic drugs.  Am J Hematol. 1985;  20(3) 257-265
    PubMedGoogle Scholar
  • 44 Wang J, Weiss I, Svoboda K, Kwaan H C. Thrombogenic role of cells undergoing apoptosis.  Br J Haematol. 2001;  115(2) 382-391
    CrossrefPubMedGoogle Scholar
  • 45 Barbui T, Finazzi G, Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia.  Blood. 1998;  91(9) 3093-3102
    PubMedGoogle Scholar
  • 46 Tallman M S, Lefebvre P, Baine R M et al.. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia.  J Thromb Haemost. 2004;  2(8) 1341-1350
    CrossrefPubMedGoogle Scholar
  • 47 Rickles F R, Falanga A. Molecular basis for the relationship between thrombosis and cancer.  Thromb Res. 2001;  102(6) V215-V224
    CrossrefPubMedGoogle Scholar
  • 48 Brusselmans K, Bono F, Collen D, Herbert J M, Carmeliet P, Dewerchin M. A novel role for vascular endothelial growth factor as an autocrine survival factor for embryonic stem cells during hypoxia.  J Biol Chem. 2005;  280(5) 3493-3499
    PubMedGoogle Scholar
  • 49 Yan S F, Mackman N, Kisiel W, Stern D M, Pinsky D J. Hypoxia/hypoxemia-induced activation of the procoagulant pathways and the pathogenesis of ischemia-associated thrombosis.  Arterioscler Thromb Vasc Biol. 1999;  19(9) 2029-2035
    PubMedGoogle Scholar
  • 50 Anderson K C. The role of immunomodulatory drugs in multiple myeloma.  Semin Hematol. 2003;  40(4 suppl 4) 23-32
    PubMedGoogle Scholar
  • 51 Anderson K C. Moving disease biology from the lab to the clinic.  Cancer. 2003;  97(3 suppl) 796-801
    CrossrefPubMedGoogle Scholar
  • 52 Anderson K C, Pazdur R, Farrell A T. Development of effective new treatments for multiple myeloma.  J Clin Oncol. 2005;  23(28) 7207-7211
    CrossrefPubMedGoogle Scholar
  • 53 Chauhan D, Uchiyama H, Akbarali Y et al.. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B.  Blood. 1996;  87(3) 1104-1112
    PubMedGoogle Scholar
  • 54 Urashima M, Ogata A, Chauhan D et al.. Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells.  Blood. 1996;  87(5) 1928-1938
    PubMedGoogle Scholar
  • 55 Podar K, Tai Y T, Davies F E et al.. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.  Blood. 2001;  98(2) 428-435
    CrossrefPubMedGoogle Scholar
  • 56 Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson K C. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.  Oncogene. 2001;  20(33) 4519-4527
    CrossrefPubMedGoogle Scholar
  • 57 Leone G, Sica S, Chiusolo P, Teofili L, De Stefano V. Blood cells diseases and thrombosis.  Haematologica. 2001;  86(12) 1236-1244
    PubMedGoogle Scholar
  • 58 de Gaetano G, Cerletti C, Evangelista V. Recent advances in platelet-polymorphonuclear leukocyte interaction.  Haemostasis. 1999;  29(1) 41-49
    CrossrefPubMedGoogle Scholar
  • 59 Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism.  Lancet Oncol. 2005;  6(6) 401-410
    CrossrefPubMedGoogle Scholar
  • 60 Beer J H, Haeberli A, Vogt A et al.. Coagulation markers predict survival in cancer patients.  Thromb Haemost. 2002;  88(5) 745-749
    PubMedGoogle Scholar
  • 61 Goldenberg N, Kahn S R, Solymoss S. Markers of coagulation and angiogenesis in cancer-associated venous thromboembolism.  J Clin Oncol. 2003;  21(22) 4194-4199
    CrossrefPubMedGoogle Scholar
  • 62 Blann A D, Gurney D, Wadley M, Bareford D, Stonelake P, Lip G Y. Increased soluble P-selectin in patients with haematological and breast cancer: a comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor.  Blood Coagul Fibrinolysis. 2001;  12(1) 43-50
    CrossrefPubMedGoogle Scholar
  • 63 Simak J, Gelderman M P. Cell membrane microparticles in blood and blood products: potentially pathogenic agents and diagnostic markers.  Transfus Med Rev. 2006;  20(1) 1-26
    CrossrefPubMedGoogle Scholar
  • 64 Horstman L L, Jy W, Jimenez J J, Bidot C, Ahn Y S. New horizons in the analysis of circulating cell-derived microparticles.  Keio J Med. 2004;  53(4) 210-230
    CrossrefPubMedGoogle Scholar
  • 65 Dixit A, Kannan M, Mahapatra M, Choudhry V P, Saxena R. Roles of protein C, protein S, and antithrombin III in acute leukemia.  Am J Hematol. 2006;  81(3) 171-174
    CrossrefPubMedGoogle Scholar
  • 66 Haim N, Lanir N, Hoffman R, Haim A, Tsalik M, Brenner B. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism.  Am J Med. 2001;  110(2) 91-96
    CrossrefPubMedGoogle Scholar
  • 67 Sarig G, Michaeli Y, Lanir N, Brenner B, Haim N. Mechanisms for acquired activated protein C resistance in cancer patients.  J Thromb Haemost. 2005;  3(3) 589-590
    CrossrefPubMedGoogle Scholar
  • 68 Green D, Maliekel K, Sushko E, Akhtar R, Soff G A. Activated-protein-C resistance in cancer patients.  Haemostasis. 1997;  27(3) 112-118
    PubMedGoogle Scholar
  • 69 Kwaan H C, Bongu A. The hyperviscosity syndromes.  Semin Thromb Hemost. 1999;  25(2) 199-208
    Article in Thieme ConnectPubMedGoogle Scholar
  • 70 Cukierman T, Gatt M E, Libster D, Goldschmidt N, Matzner Y. Chronic lymphocytic leukemia presenting with extreme hyperleukocytosis and thrombosis of the common femoral vein.  Leuk Lymphoma. 2002;  43(9) 1865-1868
    CrossrefPubMedGoogle Scholar
  • 71 Khorana A A, Francis C W, Culakova E, Lyman G H. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study.  Cancer. 2005;  104(12) 2822-2829
    CrossrefPubMedGoogle Scholar
  • 72 Chang V T, Aviv H, Howard L M, Padberg F. Acute myelogenous leukemia associated with extreme symptomatic thrombocytosis and chromosome 3q translocation: case report and review of literature.  Am J Hematol. 2003;  72(1) 20-26
    CrossrefPubMedGoogle Scholar
  • 73 Colovic N, Miljic P, Colovic M, Milosevic-Jovcic N. Multiple M components in two patients with splenic lymphoma with villous lymphocytes.  Ann Hematol. 2006;  85(1) 51-54
    PubMedGoogle Scholar
  • 74 Gomez-Puerta J A, Cervera R, Espinosa G et al.. Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients.  Semin Arthritis Rheum. 2006;  35(5) 322-332
    CrossrefPubMedGoogle Scholar
  • 75 Genvresse I, Luftner D, Spath-Schwalbe E, Buttgereit F. Prevalence and clinical significance of anticardiolipin and anti-beta2-glycoprotein-I antibodies in patients with non-Hodgkin's lymphoma.  Eur J Haematol. 2002;  68(2) 84-90
    CrossrefPubMedGoogle Scholar
  • 76 Pusterla S, Previtali S, Marziali S et al.. Antiphospholipid antibodies in lymphoma: prevalence and clinical significance.  Hematol J. 2004;  5(4) 341-346
    CrossrefPubMedGoogle Scholar
  • 77 Khan S, Dickerman J D. Hereditary thrombophilia.  Thromb J. 2006;  4 15
    CrossrefPubMedGoogle Scholar
  • 78 Simioni P, Tormene D, Spiezia L et al.. Inherited thrombophilia and venous thromboembolism.  Semin Thromb Hemost. 2006;  32(7) 700-708
    Article in Thieme ConnectPubMedGoogle Scholar
  • 79 Leroyer C, Mercier B, Oger E et al.. Prevalence of 20210 A allele of the prothrombin gene in venous thromboembolism patients.  Thromb Haemost. 1998;  80(1) 49-51
    PubMedGoogle Scholar
  • 80 Abramson N, Costantino J P, Garber J E, Berliner N, Wickerham D L, Wolmark N. Effect of Factor V Leiden and prothrombin G20210→A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.  J Natl Cancer Inst. 2006;  98(13) 904-910
    PubMedGoogle Scholar
  • 81 Elice F, Fink L, Tricot G, Barlogie B, Zangari M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism.  Br J Haematol. 2006;  134(4) 399-405
    CrossrefPubMedGoogle Scholar
  • 82 Di Micco P, Niglio A, De Renzo A et al.. Congenital and acquired thrombotic risk factors in lymphoma patients bearing upper extremities deep venous thrombosis: a preliminary report.  J Transl Med. 2004;  2(1) 7
    CrossrefPubMedGoogle Scholar
  • 83 Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients.  J Clin Oncol. 2003;  21(19) 3665-3675
    CrossrefPubMedGoogle Scholar
  • 84 Cortelezzi A, Moia M, Falanga A et al.. Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study.  Br J Haematol. 2005;  129(6) 811-817
    CrossrefPubMedGoogle Scholar
  • 85 Svensson M, Wiren M, Kimby E, Hagglund H. Portal vein thrombosis is a common complication following splenectomy in patients with malignant haematological diseases.  Eur J Haematol. 2006;  77(3) 203-209
    CrossrefPubMedGoogle Scholar
  • 86 Mohren M, Markmann I, Dworschak U et al.. Thromboembolic complications after splenectomy for hematologic diseases.  Am J Hematol. 2004;  76(2) 143-147
    CrossrefPubMedGoogle Scholar
  • 87 Zakarija A, Kwaan H C. Adverse effects on hemostatic function caused by drugs used in hematologic malignancies.  Semin Thromb Hemost. 2007;  33 355-364
    Article in Thieme ConnectPubMedGoogle Scholar
  • 88 Webert K, Cook R J, Sigouin C S, Rebulla P, Heddle N M. The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia.  Haematologica. 2006;  91(11) 1530-1537
    PubMedGoogle Scholar
  • 89 Spectre G, Libster D, Grisariu S et al.. Bleeding, obstruction, and perforation in a series of patients with aggressive gastric lymphoma treated with primary chemotherapy.  Ann Surg Oncol. 2006;  13(11) 1372-1378
    CrossrefPubMedGoogle Scholar
  • 90 Deshpande A, Storch I, Barkin J. Diagnosis of lymphoma in overt obscure GI bleeding aided by capsule endoscopy.  Gastrointest Endosc. 2007;  65(1) 159-160
    CrossrefPubMedGoogle Scholar
  • 91 Koornstra J J, Schot B W, Dijkstra G. Mantle cell lymphoma involving the appendiceal orifice as an unusual cause of lower gastrointestinal bleeding.  Int J Colorectal Dis. 2007;  22(1) 99-100
    PubMedGoogle Scholar
  • 92 Okajima K, Sakamoto Y, Uchiba M. Heterogeneity in the incidence and clinical manifestations of disseminated intravascular coagulation: a study of 204 cases.  Am J Hematol. 2000;  65(3) 215-222
    CrossrefPubMedGoogle Scholar
  • 93 Menell J S, Cesarman G M, Jacovina A T, McLaughlin M A, Lev E A, Hajjar K A. Annexin II and bleeding in acute promyelocytic leukemia.  N Engl J Med. 1999;  340(13) 994-1004
    CrossrefPubMedGoogle Scholar
  • 94 Tapiovaara H, Matikainen S, Hurme M, Vaheri A. Induction of differentiation of promyelocytic NB4 cells by retinoic acid is associated with rapid increase in urokinase activity subsequently downregulated by production of inhibitors.  Blood. 1994;  83(7) 1883-1891
    CrossrefPubMedGoogle Scholar
  • 95 Kwaan H C, Wang J, Weiss I. Expression of receptors for plasminogen activators on endothelial cell surface depends on their origin.  J Thromb Haemost. 2004;  2(2) 306-312
    CrossrefPubMedGoogle Scholar
  • 96 Dally N, Hoffman R, Haddad N, Sarig G, Rowe J M, Brenner B. Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-a single center experience in 34 patients.  Thromb Res. 2005;  116(2) 109-114
    CrossrefPubMedGoogle Scholar
  • 97 Boggio L N, Green D. Acquired hemophilia.  Rev Clin Exp Hematol. 2001;  5(4) 389-404
    CrossrefPubMedGoogle Scholar
  • 98 Collins P W, Hirsch S, Baglin T P et al.. Acquired haemophilia A in the UK: a two year national surveillance study by UK Haemophilia Centre Doctors' Organisation.  Blood. 2007;  109 1870-1877
    CrossrefPubMedGoogle Scholar
  • 99 Sallah S, Wan J Y. Inhibitors against factor VIII in patients with cancer. Analysis of 41 patients.  Cancer. 2001;  91(6) 1067-1074
    CrossrefPubMedGoogle Scholar
  • 100 Sallah S, Nguyen N P, Abdallah J M, Hanrahan L R. Acquired hemophilia in patients with hematologic malignancies.  Arch Pathol Lab Med. 2000;  124(5) 730-734
    PubMedGoogle Scholar

Hau C KwaanM.D. 

Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University

303 East Chicago Ave., Chicago, IL 60611

Email: h-kwaan@northwestern.edu

      >